Autolus Therapeutics plc - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
AUTL Nasdaq 2836 www.autolus.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Autolus Therapeutics plc

European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading; Shares Still Up This Week - Dec 12th, 2025 9:17 am
3 Promising Penny Stocks With Market Caps Over $70M - Dec 11th, 2025 5:05 am
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading - Dec 9th, 2025 9:06 am
Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025 - Dec 8th, 2025 2:05 pm
European Equities Traded in the US as ADRs Little Changed in Monday Trading - Dec 8th, 2025 9:01 am
Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025 - Dec 8th, 2025 6:35 am
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading - Dec 4th, 2025 8:59 am
European Equities Traded in the US as American Depositary Receipts Higher in Wednesday Trading - Dec 3rd, 2025 9:29 am
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading - Dec 1st, 2025 9:02 am
Autolus Therapeutics Appoints Ryan Richardson to Board of Directors - Dec 1st, 2025 5:00 am
European Equities Traded in the US as American Depositary Receipts Surge in Wednesday Trading - Nov 26th, 2025 9:03 am
European Equities Traded in the US as American Depositary Receipts Turn Sharply Higher in Tuesday Trading - Nov 25th, 2025 9:08 am
NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹ - Nov 25th, 2025 2:00 am
Is Autolus Therapeutics PLC (AUTL) One of the Fastest-Growing Penny Stocks to Buy Now? - Nov 24th, 2025 7:47 am
European Equities Traded in the US as American Depositary Receipts Down Sharply in Friday Trading - Nov 18th, 2025 9:05 am
Autolus Therapeutics plc (NASDAQ:AUTL) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year - Nov 15th, 2025 6:13 am
European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading - Nov 14th, 2025 9:02 am
How Investors Are Reacting To Autolus Therapeutics (AUTL) Trimming Losses and Appointing a New Finance Chief - Nov 13th, 2025 3:08 pm
Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference in London - Nov 13th, 2025 2:05 pm
European Equities Traded in the US as American Depositary Receipts Slightly Higher in Thursday Trading - Nov 13th, 2025 9:19 am